(Q34909902)

5 August 2017

1 reference

title

Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer (English)

1 reference

5 August 2017

1 reference

David H Kirn

1

1 reference

5 August 2017

Steve H Thorne

series ordinal

2

1 reference

5 August 2017

language of work or name

English

0 references

publication date

1 January 2009

1 reference

5 August 2017

published in

Nature Reviews Cancer

1 reference

5 August 2017

volume

9

1 reference

5 August 2017

issue

1

1 reference

5 August 2017

page(s)

64-71

1 reference

From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage.

5 August 2017

cites work

1 reference

The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma

31 March 2020

1 reference

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

31 March 2020

1 reference

New developments in multitargeted therapy for patients with solid tumours

31 March 2020

1 reference

Clinical development of gene therapy for colorectal cancer

31 March 2020

1 reference

Why did p53 gene therapy fail in ovarian cancer?

31 March 2020

1 reference

Cancer gene therapy: fringe or cutting edge?

31 March 2020

1 reference

Cancer immunotherapy: moving beyond current vaccines

31 March 2020

1 reference

Vaccination of prostate cancer patients with modified vaccinia ankara delivering the tumor antigen 5T4 (TroVax): a phase 2 trial

31 March 2020

1 reference

Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma

31 March 2020

1 reference

ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents

31 March 2020

1 reference

Getting oncolytic virus therapies off the ground

31 March 2020

1 reference

Recent progress in the battle between oncolytic viruses and tumours

31 March 2020

1 reference

Oncolytic virotherapy: approaches to tumor targeting and enhancing antitumor effects

31 March 2020

1 reference

Reovirus therapy of tumors with activated Ras pathway

31 March 2020

1 reference

Reovirus as a novel oncolytic agent

31 March 2020

1 reference

Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus

31 March 2020

1 reference

VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents

31 March 2020

1 reference

An adenovirus mutant that replicates selectively in p53-deficient human tumor cells

31 March 2020

1 reference

Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas

31 March 2020

1 reference

Reovirus: viral therapy for cancer 'as nature intended'.

31 March 2020

1 reference

ONYX-015: clinical data are encouraging

31 March 2020

1 reference

a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

31 March 2020

1 reference

Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer

31 March 2020

1 reference

Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial

31 March 2020

1 reference

Translation of targeted oncolytic virotherapeutics from the lab into the clinic, and back again: a high-value iterative loop.

31 March 2020

1 reference

Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF.

31 March 2020

1 reference

Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus

31 March 2020

1 reference

Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963

31 March 2020

1 reference

The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2.

31 March 2020

1 reference

The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma

31 March 2020

1 reference

Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial

31 March 2020

1 reference

Bioterrorism. In search of a kinder, gentler vaccine

31 March 2020

1 reference

Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines

31 March 2020

1 reference

Quantification of antibody responses against multiple antigens of the two infectious forms of Vaccinia virus provides a benchmark for smallpox vaccination

31 March 2020

1 reference

Determinants of antibody response after recombinant gp160 boosting in vaccinia-naive volunteers primed with gp160-recombinant vaccinia virus. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Clinical Trials Network

31 March 2020

1 reference

Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus--poxvirus vaccines in vaccinia-nonimmune and vaccinia-immune humans

31 March 2020

1 reference

Clinical evaluation of a vaccinia-vectored Hantaan virus vaccine

31 March 2020

1 reference

Immunisation with canarypox virus expressing rabies glycoprotein

31 March 2020

1 reference

Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria.

31 March 2020

1 reference

Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer

31 March 2020

1 reference

Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients.

31 March 2020

1 reference

Vaccinia virus uses macropinocytosis and apoptotic mimicry to enter host cells

31 March 2020

1 reference

Poxvirus entry and membrane fusion

31 March 2020

1 reference

Extracellular enveloped vaccinia virus is resistant to complement because of incorporation of host complement control proteins into its envelope.

31 March 2020

1 reference

Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin

31 March 2020

1 reference

Enhancing poxvirus oncolytic effects through increased spread and immune evasion

31 March 2020

1 reference

Vaccinia immune globulin: current policies, preparedness, and product safety and efficacy

31 March 2020

1 reference

Cidofovir in the treatment of poxvirus infections

31 March 2020

1 reference

An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge

31 March 2020

1 reference

Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases

31 March 2020

1 reference

Infectious poxvirus vectors have capacity for at least 25 000 base pairs of foreign DNA

31 March 2020

1 reference

Disruption of Erk-dependent type I interferon induction breaks the myxoma virus species barrier

31 March 2020

1 reference

Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor.

31 March 2020

1 reference

Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins

31 March 2020

1 reference

31 March 2020

The Hallmarks of Cancer

1 reference

Vaccinia virus intermediate stage transcription is complemented by Ras-GTPase-activating protein SH3 domain-binding protein (G3BP) and cytoplasmic activation/proliferation-associated protein (p137) individually or as a heterodimer

31 March 2020

1 reference

Targeted delivery of a suicide gene to human colorectal tumors by a conditionally replicating vaccinia virus

31 March 2020

1 reference

Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus

31 March 2020

1 reference

Tumor-specific gene delivery using recombinant vaccinia virus in a rabbit model of liver metastases.

31 March 2020

1 reference

Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype

31 March 2020

1 reference

Cell proliferative response to vaccinia virus is mediated by VGF.

31 March 2020

1 reference

Pathogenic poxviruses reveal viral strategies to exploit the ErbB signaling network

31 March 2020

1 reference

A mitogenic signal triggered at an early stage of vaccinia virus infection: implication of MEK/ERK and protein kinase A in virus multiplication.

31 March 2020

1 reference

A soluble receptor for interleukin-1 beta encoded by vaccinia virus: a novel mechanism of virus modulation of the host response to infection

31 March 2020

1 reference

Vaccinia virus serpin B13R (SPI-2) inhibits interleukin-1beta-converting enzyme and protects virus-infected cells from TNF- and Fas-mediated apoptosis, but does not prevent IL-1beta-induced fever

31 March 2020

1 reference

The vaccinia virus protein F1L interacts with Bim and inhibits activation of the pro-apoptotic protein Bax

31 March 2020

1 reference

A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus

31 March 2020

1 reference

Vaccinia Virus B18R Gene Encodes a Type I Interferon-binding Protein That Blocks Interferon α Transmembrane Signaling

31 March 2020

1 reference

Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificity

31 March 2020

1 reference

Stem Cells and Cancer: Two Faces of Eve

31 March 2020

1 reference

High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal

31 March 2020

1 reference

Inside, outside, upside down: damage-associated molecular-pattern molecules (DAMPs) and redox

31 March 2020

1 reference

Innate immunity against vaccinia virus is mediated by TLR2 and requires TLR-independent production of IFN-beta

31 March 2020

1 reference

Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow

31 March 2020

1 reference

Protective immunity against secondary poxvirus infection is dependent on antibody but not on CD4 or CD8 T-cell function

31 March 2020

1 reference

Oral vaccination with modified vaccinia virus Ankara attached covalently to TMPEG-modified cationic liposomes overcomes pre-existing poxvirus immunity from recombinant vaccinia immunization

31 March 2020

1 reference

Retargeting polymer-coated adenovirus to the FGF receptor allows productive infection and mediates efficacy in a peritoneal model of human ovarian cancer

31 March 2020

1 reference

Mutations in the vaccinia virus A33R and B5R envelope proteins that enhance release of extracellular virions and eliminate formation of actin-containing microvilli without preventing tyrosine phosphorylation of the A36R protein

31 March 2020

1 reference

Synergistic antitumor effects of immune cell-viral biotherapy

31 March 2020

1 reference

Tumor-targeted, systemic delivery of therapeutic viral vectors using hitchhiking on antigen-specific T cells

31 March 2020

1 reference

Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T cell therapy, oncolytic virotherapy and immunotherapy

31 March 2020

1 reference

Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity.

31 March 2020

1 reference

Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies

31 March 2020

1 reference

Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival

31 March 2020

1 reference

Cancer regression in patients after transfer of genetically engineered lymphocytes

31 March 2020

1 reference

Cancer immunotherapy with natural killer cells

31 March 2020

1 reference

Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production

31 March 2020

1 reference

Compact, synthetic, vaccinia virus early/late promoter for protein expression.

31 March 2020

1 reference

Structure of vaccinia virus late promoters

31 March 2020

1 reference

Chemical control of protein stability and function in living mice.

31 March 2020

1 reference

Selective intratumoral amplification of an antiangiogenic vector by an oncolytic virus produces enhanced antivascular and anti-tumor efficacy

31 March 2020

1 reference

Relaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction, and efficacy

31 March 2020

1 reference

Complex interactions between the replicating oncolytic effect and the enzyme/prodrug effect of vaccinia-mediated tumor regression

31 March 2020

1 reference

Oncolytic virotherapy for ovarian carcinomatosis using a replication-selective vaccinia virus armed with a yeast cytosine deaminase gene

31 March 2020

1 reference

Vaccinia virus immune evasion

31 March 2020

1 reference

Using in Vivo Bioluminescence Imaging to Shed Light on Cancer Biology

31 March 2020

1 reference

Bioluminescence imaging of vaccinia virus: effects of interferon on viral replication and spread

31 March 2020

1 reference

Adenovirus biodistribution and noninvasive imaging of gene expression in vivo by positron emission tomography using human sodium/iodide symporter as reporter gene

31 March 2020

1 reference

Oncolytic vaccinia virus expressing the human somatostatin receptor SSTR2: molecular imaging after systemic delivery using 111In-pentetreotide

31 March 2020

1 reference

In vivo magnetic resonance imaging of transgene expression.

31 March 2020

1 reference

Myopericarditis following smallpox vaccination among vaccinia-naive US military personnel

31 March 2020

1 reference

Poxvirus vaccines for cancer and HIV therapy

31 March 2020

1 reference

Pox viral vaccine approaches.

31 March 2020

1 reference

Use of Vaccinia Virus in the Treatment of Metastatic Malignant Melanoma

31 March 2020

1 reference

Intralesional vaccinia/GM-CSF recombinant virus in the treatment of metastatic melanoma

31 March 2020

1 reference

The experimental local therapy of cutaneous metastases of malignant melanoblastomas with cow pox vaccine or colcemid (demecolcine or omaine)

31 March 2020

1 reference

Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma

31 March 2020

1 reference

Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.

31 March 2020

1 reference

CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor--armed oncolytic adenovirus for the treatment of bladder cancer

31 March 2020

1 reference

A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor.

31 March 2020

1 reference

An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy

31 March 2020

1 reference

12 December 2020

Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant

1 reference

12 December 2020

Dissociation of progeny vaccinia virus from the cell membrane is regulated by a viral envelope glycoprotein: effect of a point mutation in the lectin homology domain of the A34R gene

1 reference

12 December 2020

Intravesical gene therapy: in vivo gene transfer using recombinant vaccinia virus vectors

1 reference

12 December 2020

Virus combinations and chemotherapy for the treatment of human cancers.

1 reference

12 December 2020

Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes.

1 reference

12 December 2020

Stem cells: the real culprits in cancer?

1 reference

12 December 2020

Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction

1 reference

12 December 2020

Smallpox vaccination and adverse reactions. Guidance for clinicians.

1 reference

12 December 2020

Poxvirus pathogenesis

1 reference

12 December 2020

Drug evaluation: Therion's rV-PSA-TRICOM + rF-PSA-TRICOM prime-boost prostate cancer vaccine

1 reference

12 December 2020

Poxviruses as vectors for cancer immunotherapy.

1 reference

12 December 2020

Different regulation of thymidine kinase during the cell cycle of normal versus DNA tumor virus-transformed cells.

1 reference

12 December 2020

Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints

1 reference

12 December 2020

Systemic administration of a recombinant vaccinia virus expressing the cytosine deaminase gene and subsequent treatment with 5-fluorocytosine leads to tumor-specific gene expression and prolongation of survival in mice.

1 reference

12 December 2020

Validation and analysis of a mathematical model of a replication-competent oncolytic virus for cancer treatment: implications for virus design and delivery

1 reference

12 December 2020

Spying on cancer: molecular imaging in vivo with genetically encoded reporters

1 reference

12 December 2020

A triad of costimulatory molecules synergize to amplify T-cell activation

1 reference

12 December 2020

Immunotherapy of Malignant Melanoma With Vaccinia Virus

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRC2545

1 reference

Dimensions Publication ID

5 August 2017

1015008895

0 references

1 reference